Anifrolumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Anifrolumab and local guidelines before prescribing.

Biologic (type I IFN)

Mechanism

Type I interferon receptor antibody.

Uses

Moderate to severe SLE.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Respiratory infections, herpes zoster, infusion reactions.

Interactions

Live vaccines contraindicated.

Contraindications and cautions

Active infection

Monitoring

Disease activity

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive

Special advice

Not for severe nephritis or neuropsychiatric lupus.

More from the textbook: uses, cautions and other points
Where it is discussed in the book